Bildgebung in der zirrhotischen Leber – warum, wie und was ist LI-RADS?

Zusammenfassung

Die Leberzirrhose als Endstadium einer chronischen Lebererkrankung ist eine häufige Diagnose, vor allem, wenn sie auf viralen Entzündungen und Alkoholabusus basiert. Ein umfassendes Verständnis dieser Erkrankung sollte eine Voraussetzung für eine gute radiologische Diagnostik sein. Auch das LI-RADS-System, das bei Patienten mit hohem HCC-Risiko und Leberzirrhose eingesetzt wird, sollte in einer strukturierten radiologischen Befundung Einzug halten.

Abstract

Liver cirrhosis represents a final stage of chronic liver diseases. The most common causes are viral infections and alcohol. In this review article we describe the most common causes and complications of liver cirrhosis. We explain the carcinogenesis of the hepatocellular carcinoma in a cirrhotic liver as a maximum complication. Based on this foundation we describe optimal imaging strategies for CT and MR-Imaging in patients with liver cirrhosis. We complete the review with a state-of-the-art assessment and explanation of the recently introduced LI-RADS criteria for structured reporting.

Schlüsselwörter

Leberzirrhose - hepatozelluläres Karzinom - LI-RADS

Key words

liver cirrhosis - hepatocellular carcinoma - LI-RADS

• Literatur

• 1 DʼAmico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-231
• 2 Gerbes AL, Labenz J, Appenrodt B. et al. [Updated S2 k-Guideline “Complications of liver cirrhosis”. German Society of Gastroenterology (DGVS)]. Z Gastroenterol 2019; 57: 611-680
• 3 European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69: 406-460
• 4 Wehmeyer MH, Krohm S, Kastein F. et al. Prediction of spontaneous bacterial peritonitis in cirrhotic ascites by a simple scoring system. Scand J Gastroenterol 2014; 49: 595-603
• 5 Nagueh SF, Smiseth OA, Appleton CP. et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2016; 17: 1321-1360
• 6 Spangenberg HC, Thimme R, Blum HE. Der Leberrundherd. Dtsch Arztebl Int 2009; 34a-34i
• 7 International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995; 22: 983-993
• 8 Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology 2014; 272: 635-654
• 9 Van Beers BE, Pastor CM, Hussain HK. Primovist, Eovist: what to expect?. J Hepatol 2012; 57: 421-429
• 10 Gupta AA, Kim DC, Krinsky GA. et al. CT and MRI of cirrhosis and its mimics. AJR Am J Roentgenol 2004; 183: 1595-1601
• 11 Ito K, Mitchell DG, Siegelman ES. Cirrhosis: MR imaging features. Magn Reson Imaging Clin N Am 2002; 10: 75-92 vi
• 12 Honda H, Onitsuka H, Masuda K. et al. Chronic liver disease: value of volumetry of liver and spleen with computed tomography. Radiat Med 1990; 8: 222-226
• 13 Kudo M, Zheng RQ, Kim SR. et al. Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosis. A multicenter collaborative study. Intervirology 2008; 51 Suppl 1: 17-26
• 14 Awaya H, Mitchell DG, Kamishima T. et al. Cirrhosis: modified caudate-right lobe ratio. Radiology 2002; 224: 769-774
• 15 Zhang Y, Zhang XM, Prowda JC. et al. Changes in hepatic venous morphology with cirrhosis on MRI. J Magn Reson Imaging 2009; 29: 1085-1092
• 16 Krinsky GA, Lee VS, Theise ND. et al. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. Radiology 2001; 219: 445-454
• 17 Matsui O, Kadoya M, Kameyama T. et al. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 1991; 178: 493-497
• 18 Lim JH, Kim CK, Lee WJ. et al. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic livers: accuracy of helical CT in transplant patients. AJR Am J Roentgenol 2000; 175: 693-698
• 19 Oliver 3rd JH, Baron RL. Helical biphasic contrast-enhanced CT of the liver: technique, indications, interpretation, and pitfalls. Radiology 1996; 201: 1-14
• 20 Ronzoni A, Artioli D, Scardina R. et al. Role of MDCT in the diagnosis of hepatocellular carcinoma in patients with cirrhosis undergoing orthotopic liver transplantation. AJR Am J Roentgenol 2007; 189: 792-798
• 21 Wachsberg RH, Bahramipour P, Sofocleous CT. et al. Hepatofugal flow in the portal venous system: pathophysiology, imaging findings, and diagnostic pitfalls. Radiographics 2002; 22: 123-140
• 22 Elsayes KM, Narra VR, Mukundan G. et al. MR imaging of the spleen: spectrum of abnormalities. Radiographics 2005; 25: 967-982
• 23 Sangster GP, Previgliano CH, Nader M. et al. MDCT Imaging Findings of Liver Cirrhosis: Spectrum of Hepatic and Extrahepatic Abdominal Complications. HPB Surg 2013; 2013: 129396
• 24 Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022
• 25 Forner A, Vilana R, Ayuso C. et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008; 47: 97-104
• 26 Marrero JA, Hussain HK, Nghiem HV. et al. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl 2005; 11: 281-289
• 27 Khan AS, Hussain HK, Johnson TD. et al. Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver. J Magn Reson Imaging 2010; 32: 360-366
• 28 Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 2014; 273: 30-50
• 29 Motosugi U, Bannas P, Sano K. et al. Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma. J Magn Reson Imaging 2015; 41: 251-265
• 30 Choi JW, Lee JM, Kim SJ. et al. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker. Radiology 2013; 267: 776-786
• 31 Kogita S, Imai Y, Okada M. et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 2010; 20: 2405-2413
• 32 [Anonym] American College of Radiology. LI-RADS. Im Internet (Stand: 04.12.2021): https://www.acr.org/clinical-resources/reporting-and-data-system/LI-RADS
• 33 Ringe KI, Gut A, Grenacher L. et al. LI-RADS in the year 2020 – Are you already using it or still considering?. Rofo 2021; 193: 186-193
• 34 [Anonym] Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome, Langversion 2.0, 2021, AWMF Registernummer: 032/053OL. Im Internet (Stand: 04.12.2021): https://www.leitlinienprogramm-onkologie.de/leitlinien/hcc-und-biliäre-karzinome